For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those ...

Madison have reported a new approach to forming carbon-nitrogen bonds, a critical step in the synthesis of amines widely used ...

Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease ...

A novel microphysiological system using ovarian follicles enables physiologically relevant three-dimensional angiogenesis ...

Aaron Wenger is a senior director and principal scientist at Pacific Biosciences, where he oversees the long-read sequencing ...

All Opinion and interviews articles in Drug Target Review ...

A new study has revealed that age-related clonal haematopoiesis accelerates aortic aneurysm growth through RANK/RANKL signalling, meaning that repurposing osteoporosis drugs targeting this pathway ...

NAMs are now part of early drug discovery, but adoption remains uneven. Join leading experts for a discussion on current applications, limitations and what is required for wider use. The session ...

ELRIG is launching its first major US event, Drug Discovery USA 2026, at Pfizer’s Cambridge, Massachusetts facility on 16–17 June. The free-to-attend conference will bring together European and ...

Researchers at the University of Wisconsin–Madison have reported a new approach to forming carbon–nitrogen bonds, a critical step in the synthesis of amines widely used in pharmaceuticals, ...

For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously ...

New research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both ...